Literature DB >> 12667391

Primary gout in Shantou: a clinical and epidemiological study.

Qingyu Zeng1, Qingwen Wang, Ren Chen, Zhengyu Xiao, Shaobi Huang, Jingcai Xu.   

Abstract

OBJECTIVE: To evaluate the prevalence of primary gout in the Shantou area, China, and to understand its clinical features.
METHODS: Samples from three surveys of the Chenghai across ten years were studied. Clinical, laboratory and radiology data of 419 cases of primary gout were collected and analyzed.
RESULTS: Prevalence of primary gout in the three surveys were 0.17%, 0.15% and 0.26%, respectively. Among the clinical patients, the ratio of male to female was 21:1; the average age of onset of women was significantly higher than that of men. The number of cases in the last ten years has been increasing. In the first wave of cases, the first metatarsophalangeal joint was involved in 82.1% of all cases; no fourth metatarsophalangeal joint involvement had been observed. Hyperlipemia was the most common accompanying abnormal laboratory test (57.1%). Radiographic bone erosion was found in 49.4% patients, most of them with disease duration more than 5 years.
CONCLUSIONS: The prevalence of primary gout in Shantou area has been increasing in the last ten years. Changes in diet and lifestyle may be responsible for this rapid increase.

Entities:  

Mesh:

Year:  2003        PMID: 12667391

Source DB:  PubMed          Journal:  Chin Med J (Engl)        ISSN: 0366-6999            Impact factor:   2.628


  14 in total

Review 1.  The distribution of urate deposition within the extremities in gout: a review of 148 dual-energy CT cases.

Authors:  Paul I Mallinson; Adrian C Reagan; Tyler Coupal; Peter L Munk; Hugue Ouellette; Savvas Nicolaou
Journal:  Skeletal Radiol       Date:  2013-12-12       Impact factor: 2.199

Review 2.  Difficult-to-treat gouty arthritis: a disease warranting better management.

Authors:  Naomi Schlesinger
Journal:  Drugs       Date:  2011-07-30       Impact factor: 9.546

Review 3.  Global epidemiology of gout: prevalence, incidence and risk factors.

Authors:  Chang-Fu Kuo; Matthew J Grainge; Weiya Zhang; Michael Doherty
Journal:  Nat Rev Rheumatol       Date:  2015-07-07       Impact factor: 20.543

Review 4.  Determinants of the prevalence of gout in the general population: a systematic review and meta-regression.

Authors:  José M A Wijnands; Wolfgang Viechtbauer; Kristof Thevissen; Ilja C W Arts; Pieter C Dagnelie; Coen D A Stehouwer; Sjef van der Linden; Annelies Boonen
Journal:  Eur J Epidemiol       Date:  2014-07-27       Impact factor: 8.082

5.  Sleep Apnea and the Risk of Incident Gout: A Population-Based, Body Mass Index-Matched Cohort Study.

Authors:  Yuqing Zhang; Christine E Peloquin; Maureen Dubreuil; Edward Roddy; Na Lu; Tuhina Neogi; Hyon K Choi
Journal:  Arthritis Rheumatol       Date:  2015-12       Impact factor: 10.995

6.  Questionnaire survey evaluating disease-related knowledge for 149 primary gout patients and 184 doctors in South China.

Authors:  Qian-Hua Li; Lie Dai; Zhao-Xia Li; Hai-Jun Liu; Chan-Juan Zou; Xia Ou-Yang; Meng Lu; Ting Li; Yan-Hua Li; Yin-Qian Mo; H Ralph Schumacher
Journal:  Clin Rheumatol       Date:  2013-07-16       Impact factor: 2.980

7.  A meta-analysis of the association between gout, serum uric acid level, and obstructive sleep apnea.

Authors:  Tingting Shi; Min Min; Chenyu Sun; Ce Cheng; Yun Zhang; Mingming Liang; Feras Kamel Rizeq; Yehuan Sun
Journal:  Sleep Breath       Date:  2019-03-22       Impact factor: 2.816

Review 8.  Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.

Authors:  John S Bomalaski; Mike A Clark
Journal:  Curr Rheumatol Rep       Date:  2004-06       Impact factor: 4.592

Review 9.  Prevalence of rheumatic diseases and disability in China.

Authors:  Yao-Jun Xiang; Sheng-Ming Dai
Journal:  Rheumatol Int       Date:  2008-12-06       Impact factor: 2.631

Review 10.  New developments in the epidemiology and genetics of gout.

Authors:  Raihana Zaka; Charlene J Williams
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.686

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.